Measuring the Incremental Cost of Clinical Cancer Research
Evidence suggests that insurers limit access to clinical trials because of cost concerns. Denial of coverage for treatment in a clinical trial limits patient access to trials and could limit clinical research. Public and private efforts are underway to change these policies, but their status is unclear, although preliminary estimates suggest that such changes would not be expensive. Previous studies found that treatment costs in clinical trials are similar to costs of standard therapy; however, it is difficult to generalize from these studies. As part of the Cost of Cancer Treatment Study, an ongoing effort to produce generalizable estimates of the incremental costs of government-sponsored cancer trials, the authors are conducting a one-year retrospective study of costs for 1,500 cancer patients recruited from a randomly selected sample of institutions in the U.S. The results of the study should be of great interest to insurers and the research community as they consider permanent ways to finance cancer trials.
- Copyright: RAND Corporation
- Availability: Available
- Print Format: Paperback
- Paperback Pages: 6
- List Price: Free
- Document Number: RP-944-1
- Year: 2001
- Series: Reprints
Originally published in: Journal of Clinical Oncology, v. 19, no. 1, January 1, 2001, pp. 105-110.
This report is part of the RAND Corporation reprint series. This product is part of the RAND Corporation reprint series. RAND reprints present previously published journal articles, book chapters, and reports with the permission of the publisher. RAND reprints have been formally reviewed in accordance with the publisher's editorial policy, and are compliant with RAND's rigorous quality assurance standards for quality and objectivity.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.